- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01489124
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
This is prospective, randomized and crossover design to assess the pharmacokinetic and pharmacodynamics of three regimen.
- 0.5-hr infusion of imipenem 0.5 g every 6 hrs
- 2-hr infusion of imipenem 0.5 g every 6 hrs
- 2-hr infusion of imipenem 1 g every 6 hrs
Clinical and laboratory data such as Age,Sex, Body weight, CBC, Electrolyte, Vital signs, APACHE II score, BUN, Cr, Sample and Blood culture will be collected.
Nine patients will be enrolled in this study. After completion of the imipenem therapy for 3 days in this study, all patients will receive other sensitive antibiotics to eradicate their bacterial infections.
Blood samples (approximately 3 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 5 and 6 after 4th dose of imipenem.
Concentration of imipenem in plasma will be measured by HPLC method. Then, the data will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Introduction: Ventilator-associated pneumonia (VAP) is a common cause of nosocomial infection with a high mortality rate. In the current era of increasing highly resistant pathogens in nosocomial infections, the empirical treatment of these organisms is becoming more difficult and only a few novel antimicrobial agents are currently in development with activity against these highly resistant Gram negative bacilli infections. Imipenem, a carbapenem antibiotic, is a β-lactam antibacterial agent with a broad spectrum of activity against both Gram positive and Gram negative bacteria. This agent is still one of the most commonly used antibiotics for empirical therapy of highly resistant nosocomial infections in VAP. In common with other β-lactams, imipenem exhibits primarily time dependent killing and increasing the concentration of this agent does not necessarily increase the rate and extent of bacterial killing. Therefore, the time that concentrations in serum are above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with efficacy. Pharmacodynamic analysis can be applied to imipenem dosages to increase the likelihood of optimal exposure and achieve good clinical responses in patients with VAP. Previous studies we performed found that a 2 h infusion of carbapenem antibiotics gave greater values for T>MIC than a 0.5 h infusion. Therefore, in an attempt to improve the efficacy of the present β-lactam antimicrobial agents such as imipenem, a prolonged infusion would be the appropriate mode for administration to promote the maximal bactericidal effect.PK changes have been found for several hydrophilic antimicrobial agents in critically ill patients. Drug dispositions are altered in this patient population when compared with healthy subjects leading to fluctuations of plasma concentrations. Therefore, the aim of this study was to assess the PD of imipenem in VAP patients, comparing administration by 0.5 h infusion or 2 h infusion.
Objectives: To assess the pharmacokinetic and pharmacodynamics of three regimen as below.
i) 0.5-hr infusion of imipenem 0.5 g every 6 hrs ii) 2-hr infusion of imipenem 0.5 g every 6 hrs iii) 2-hr infusion of imipenem 1 g every 6 hrs
Drug preparation:Imipenem will be reconstituted with 100 ml saline solution according to the manufacturer's guidelines
Study design: This is prospective, randomized and crossover design to assess
Each patients will receive doripenem in 3 regimens consecutively:
i) 0.5-hr infusion of imipenem 0.5 g every 6 hrs ii) 2-hr infusion of imipenem 0.5 g every 6 hrs iii) 2-hr infusion of imipenem 1 g every 6 hrs
Nine patients will be enrolled in this study. After completion of the imipenem therapy for 3 days in this study, all patients will receive other sensitive antibiotics to eradicate their bacterial infections.
Sample collections: Blood samples (approximately 3 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 5 and 6 after 4th dose of imipenem. All blood samples will be allowed to clot and then centrifuged at 2,000g. The serum obtained will be stored at-80°C until analysis.
Imipenem assays by HPLC method e performed at Department of Medicine, Faculty of Medicine.
Clinical and laboratory data such as Age,Sex, Body weight, CBC, Electrolyte, Vital signs, APACHE II score, BUN, Cr, Sample and Blood culture will be collected.
Duration of study: Patients will receive imipenem for 3 days
Pharmacokinetic and pharmacodynamic analysis: Concentration of imipenem in plasma will be measured by HPLC method and simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response).
Sample Size: Nine patients with VAP will be enrolled in this study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Songkla
-
Hat Yai, Songkla, Tailandia, 90110
- Prince of Songkla University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients aged ≥ 18 years
- Patients are intubated and receiving mechanical ventilation.
- Patients have clinical suspicion of VAP with Gram negative bacilli infections, defined by a new and persistent infiltrate on chest radiography associated with at least one of the following: purulent tracheal secretions, temperature of 38.3°C or higher or a leucocyte count higher than 10000 cells/mm3.
- Expected life expectancy ≥ 3 days
Exclusion Criteria:
- Patients have documented hypersensitivity to imipenem or other carbapenems.
- Patients have an estimated creatinine clearance < 60 ml/min
- Patients are in circulatory shock (defined as a systolic blood pressure of < 90 mmHg).
- Patients are pregnant.
- Pretient receive imipenem for 2 weeks before randomization.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 0.5 g of imipenem by 0.5-hr infusion
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
|
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Otros nombres:
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
|
Experimental: 0.5 g of imipenem by 2-hr infusion
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
|
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Otros nombres:
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
|
Experimental: 1 g of imipenem by 2-hr infusion
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
|
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Otros nombres:
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Efficacy of imipenem administration by a 0.5 h and 2 h infusion
Periodo de tiempo: At 0, 0.5, 1, 2, 3, 4, 5 and 6 hours after 4th dose of imipenem.
|
Concentration of imipenem in plasma will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Fraction Response).
|
At 0, 0.5, 1, 2, 3, 4, 5 and 6 hours after 4th dose of imipenem.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Infecciones
- Infecciones del Tracto Respiratorio
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Atributos de la enfermedad
- Infección cruzada
- Enfermedad iatrogénica
- Neumonía asociada a la atención médica
- Neumonía
- Neumonía asociada a ventilador
- Agentes antiinfecciosos
- Agentes antibacterianos
- Imipenem
Otros números de identificación del estudio
- IMI-50-372-028
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Imipenem
-
Tunis UniversityTerminadoNeumonía asociada a ventiladorTúnez
-
Assistance Publique - Hôpitaux de ParisTerminadoNeumonía asociada al ventiladorFrancia
-
Central Hospital, Nancy, FranceTerminado
-
Institute of Liver and Biliary Sciences, IndiaTerminadoPeritonitis bacteriana espontáneaIndia
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and Development; Fond...TerminadoNeutropenia febril | Malignidad hematológicaPaíses Bajos
-
Juan A. ArnaizTerminadoEndocarditis infecciosaEspaña
-
University of Puerto RicoDesconocidoEnfermedad crítica | Trauma | Infección resistentePuerto Rico
-
University Hospital RijekaUniversity of RijekaTerminado
-
Assistance Publique - Hôpitaux de ParisGroupe Hospitalier Paris Saint Joseph; French National Network of Clinical Research...TerminadoInfecciones del tracto urinarioFrancia
-
Entasis TherapeuticsTerminadoBacteriemia | Neumonía bacteriana asociada al ventilador | Complejo Acinetobacter Baumannii-calcoaceticus | Neumonía bacteriana adquirida en el hospital | ABC resistente a la colistinaEstados Unidos, Bielorrusia, Brasil, Porcelana, Grecia, Hungría, India, Israel, Corea, república de, Lituania, México, Perú, Puerto Rico, Federación Rusa, Taiwán, Tailandia, Pavo